Fighting prostate cancer with gut bacteria: new trial aims to beat drug resistance
NCT ID NCT06616597
Summary
This study is testing whether adding one or two common medications (dexamethasone and metronidazole) to a standard prostate cancer drug (abiraterone) can help overcome resistance that sometimes develops. It is for men whose metastatic prostate cancer has stopped responding to abiraterone. Researchers believe bacteria in the gut might be producing hormones that help the cancer resist treatment, and these added drugs aim to block that process.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
RECRUITINGBaltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.